Paratek Pharmaceuticals Inc. (PRTK)’s Financial Results Comparing With Portola Pharmaceuticals Inc. (NASDAQ:PTLA)

Both Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and Portola Pharmaceuticals Inc. (NASDAQ:PTLA) are Biotechnology companies, competing one another. We will compare their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Paratek Pharmaceuticals Inc. 5.17M 45.18 111.46M -3.64 0.00
Portola Pharmaceuticals Inc. 34.63M 56.85 353.46M -5.38 0.00

Table 1 highlights Paratek Pharmaceuticals Inc. and Portola Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Paratek Pharmaceuticals Inc. -2,155.90% -132.5% -44.6%
Portola Pharmaceuticals Inc. -1,020.68% -136.3% -69.7%

Risk & Volatility

Paratek Pharmaceuticals Inc. is 3.00% more volatile than Standard and Poor’s 500 because the company has a beta of 1.03. Competitively, Portola Pharmaceuticals Inc.’s beta is 2.04 which is 104.00% more volatile than Standard and Poor’s 500.


The Current Ratio and Quick Ratio of Paratek Pharmaceuticals Inc. are 11.4 and 11.4 respectively. Its competitor Portola Pharmaceuticals Inc.’s Current Ratio is 6.6 and its Quick Ratio is 6.5. Paratek Pharmaceuticals Inc. can pay off short and long-term obligations better than Portola Pharmaceuticals Inc.

Analyst Ratings

In next table is delivered Paratek Pharmaceuticals Inc. and Portola Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Paratek Pharmaceuticals Inc. 0 1 1 2.50
Portola Pharmaceuticals Inc. 0 2 0 2.00

$13.5 is Paratek Pharmaceuticals Inc.’s consensus target price while its potential upside is 86.46%. Meanwhile, Portola Pharmaceuticals Inc.’s consensus target price is $31, while its potential upside is 4.59%. The data provided earlier shows that Paratek Pharmaceuticals Inc. appears more favorable than Portola Pharmaceuticals Inc., based on analyst opinion.

Institutional & Insider Ownership

Institutional investors owned 82.6% of Paratek Pharmaceuticals Inc. shares and 0% of Portola Pharmaceuticals Inc. shares. 2.9% are Paratek Pharmaceuticals Inc.’s share owned by insiders. Insiders Competitively, owned 1.3% of Portola Pharmaceuticals Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Paratek Pharmaceuticals Inc. -9.11% -11.05% -31.2% -36.88% -61.02% -61.56%
Portola Pharmaceuticals Inc. -4.39% 9.6% -24.91% -51.31% -60.37% -57.09%

For the past year Portola Pharmaceuticals Inc. has weaker performance than Paratek Pharmaceuticals Inc.


Paratek Pharmaceuticals Inc. beats Portola Pharmaceuticals Inc. on 7 of the 12 factors.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; and Dermavant Sciences GmbH. The company was founded in 2003 and is headquartered in South San Francisco, California.